What is the 13F Pro Quality Score for ENSC?

13F Pro ranks Ensysce Biosciences, Inc. (ENSC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENSC's current score at https://13fpro.ai/research/ENSC (free sign-up required for the full ranking).

Where does 13F Pro source ENSC data?

All Ensysce Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Ensysce Biosciences, Inc. files with the SEC under CIK 1716947. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENSC in?

Ensysce Biosciences, Inc. (ENSC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENSC research updated on 13F Pro?

ENSC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ensysce Biosciences, Inc.(ENSC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1716947 ENSC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $5.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ENSC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ensysce Biosciences, Inc. (ENSC), a Healthcare sector company. ENSC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $5.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Ensysce Biosciences, Inc. reports quarterly revenue of $961.0K, net income of $-3.6M, free cash flow of $-3.5M. Top institutional holders of ENSC by reported 13-F value include ADAGE CAPITAL PARTNERS GP, L.L.C., PERCEPTIVE ADVISORS, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. ENSC trades on the Nasdaq exchange and files with the SEC under CIK 1716947. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENSC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ensysce Biosciences, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$961.0K

Net Income

Q1 2026

$-3.6M

Free Cash Flow

Q1 2026

$-3.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-36.8% YoY

$2.2MFY 2023

FY19 —FY20 $3.9MFY21 $3.5MFY23 $2.2M

Net Income

—FY 2023

FY19 $366.0KFY20 $4.3MFY21 —FY23 —

Operating Income

+46.1% YoY

$-10.7MFY 2023

FY19 $-3.3MFY20 $-1.6MFY21 $-19.9MFY23 $-10.7M

EPS (Diluted)

-195.4% YoY

$-2.01FY 2023

FY19 —FY20 $0.00FY21 $-0.68FY23 $-2.01

Total Assets

-83.5% YoY

$2.7MFY 2023

FY19 $196.5MFY20 $351.8KFY21 $16.4MFY23 $2.7M

Op. Cash Flow

-30.8% YoY

$-10.8MFY 2023

FY19 $-1.4MFY20 $-1.2MFY21 $-8.2MFY23 $-10.8M

Metric	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$2.2M -36.8%	$3.5M -10.2%	$3.9M	—	—
Net Income	—	—	$4.3M +1078.0%	$366.0K -82.8%	$2.1M
Operating Income	$-10.7M +46.1%	$-19.9M -1131.7%	$-1.6M +51.5%	$-3.3M -247.0%	$-959.2K
EPS (Diluted)	$-2.01 -195.4%	$-0.68	$0.00	—	—
Total Assets	$2.7M -83.5%	$16.4M +4566.6%	$351.8K -99.8%	$196.5M -4.1%	$204.8M
Operating Cash Flow	$-10.8M -30.8%	$-8.2M -560.8%	$-1.2M +12.5%	$-1.4M -15.1%	$-1.2M

AI Insight: ENSC Financial Trends

Ensysce burning cash with minimal revenue; equity eroded to near-zero by Q1 2026.

• Revenue remains negligible, ranging $0–3M across 8 quarters with no growth trajectory evident.

• Operating income consistently negative, ranging $-4M to $1M; Q1 2026 posted $-4M op loss.

• Operating cash flow deteriorated to $-4M in Q1 2026, worst quarter on record since Q2 2024.

⚠ Equity collapsed from $7M (Q3 2024) to near-zero ($-0M) in Q1 2026; solvency at critical risk.

⚠ No debt disclosed but persistent operating losses suggest imminent dilution or restructuring pressure.

AI Insight: ENSC Ratio Trends

Ensysce swung to severe operating losses in 2025, with OpMargin deteriorating from +18.9% in Q3 2024 to -147.8% in Q4 2025.

• Operating margin collapsed from 18.9% in Q3 2024 to -149.1% in Q1 2025, remaining deeply negative through Q4 2025 at -147.8%.

• ROIC of 37.3% in Q3 2024 disappeared entirely by Q1 2025; no ROIC data reported in subsequent quarters.

⚠ Sustained triple-digit negative operating margins across three consecutive quarters (Q1–Q4 2025) signal structural profitability crisis.

⚠ Complete absence of ROE, ROA, ROIC, and D/E data in recent quarters obscures balance sheet and capital structure health.

Get alerted when ENSC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ensysce Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENSC

ADAGE CAPITAL PARTNERS GP, L.L.C.
$80.6K149,711 sh
PERCEPTIVE ADVISORS LLC
$46.7K86,666 sh
GEODE CAPITAL MANAGEMENT, LLC
$39.8K73,880 sh
CITADEL ADVISORS LLC
$30.9K57,363 sh
XTX Topco Ltd
$13.1K24,363 sh
VANGUARD FIDUCIARY TRUST CO
$12.9K23,854 sh
JANE STREET GROUP, LLC
$7.3K13,570 sh
TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC
$7.0K13,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.9K12,854 sh
UBS Group AG
$4.7K8,791 sh

Fund	Value	Shares
ADAGE CAPITAL PARTNERS GP, L.L.C.	$80.6K	149,711
PERCEPTIVE ADVISORS LLC	$46.7K	86,666
GEODE CAPITAL MANAGEMENT, LLC	$39.8K	73,880
CITADEL ADVISORS LLC	$30.9K	57,363
XTX Topco Ltd	$13.1K	24,363
VANGUARD FIDUCIARY TRUST CO	$12.9K	23,854
JANE STREET GROUP, LLC	$7.3K	13,570
TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC	$7.0K	13,000
VANGUARD CAPITAL MANAGEMENT LLC	$6.9K	12,854
UBS Group AG	$4.7K	8,791

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENSC on your watchlist

Track score changes the day Ensysce Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENSC a good stock to buy?

13F Pro's AI-powered analysis of Ensysce Biosciences, Inc. (ENSC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENSC are available on the ENSC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ENSC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENSC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ensysce Biosciences, Inc.'s investment landscape.